Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …

Background Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …

Background Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus
ritonavir (NMV-r) in high-risk nonhospitalized unvaccinated patients reduced the risk of …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …